Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Up 2.1 %

Shares of Akari Therapeutics stock opened at $3.43 on Wednesday. Akari Therapeutics has a twelve month low of $1.08 and a twelve month high of $4.95. The firm’s 50-day moving average price is $3.29 and its 200 day moving average price is $2.36.

Institutional Trading of Akari Therapeutics

An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC grew its holdings in Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,628 shares of the biopharmaceutical company’s stock after purchasing an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned about 1.55% of Akari Therapeutics worth $273,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.06% of the company’s stock.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.